Norway
· Delayed Price · Currency is NOK Nykode Therapeutics AS Statistics
Total Valuation
Nykode Therapeutics AS has a market cap or net worth of NOK 2.10 billion. The enterprise value is 699.00 million.
| Market Cap | 2.10B |
| Enterprise Value | 699.00M |
Important Dates
The last earnings date was Wednesday, August 28, 2024.
| Earnings Date | Aug 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Nykode Therapeutics AS has 326.55 million shares outstanding. The number of shares has increased by 17.11% in one year.
| Shares Outstanding | 326.55M |
| Shares Change (YoY) | +17.11% |
| Shares Change (QoQ) | +23.59% |
| Owned by Insiders (%) | 16.69% |
| Owned by Institutions (%) | 17.66% |
| Float | 143.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.70 |
| PB Ratio | 1.30 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.73 |
| EV / Sales | 10.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.74 |
Financial Position
The company has a current ratio of 9.28, with a Debt / Equity ratio of 3.15.
| Current Ratio | 9.28 |
| Quick Ratio | 9.28 |
| Debt / Equity | 3.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -272.46 |
Financial Efficiency
Return on equity (ROE) is -25.99% and return on invested capital (ROIC) is -24.31%.
| Return on Equity (ROE) | -25.99% |
| Return on Assets (ROA) | -19.95% |
| Return on Capital (ROIC) | -24.31% |
| Revenue Per Employee | 387,918 |
| Profits Per Employee | -2.26M |
| Employee Count | 173 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.11% in the last 52 weeks. The beta is 1.44, so Nykode Therapeutics AS's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | -77.11% |
| 50-Day Moving Average | 12.43 |
| 200-Day Moving Average | 15.55 |
| Relative Strength Index (RSI) | 26.07 |
| Average Volume (20 Days) | 3,768,688 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nykode Therapeutics AS had revenue of NOK 69.44 million and -404.04 million in losses. Loss per share was -1.29.
| Revenue | 69.44M |
| Gross Profit | 69.44M |
| Operating Income | -627.15M |
| Pretax Income | -509.45M |
| Net Income | -404.04M |
| EBITDA | -619.58M |
| EBIT | -627.15M |
| Loss Per Share | -1.29 |
Balance Sheet
The company has 1.45 billion in cash and 51.00 million in debt, giving a net cash position of 1.40 billion or 4.30 per share.
| Cash & Cash Equivalents | 1.45B |
| Total Debt | 51.00M |
| Net Cash | 1.40B |
| Net Cash Per Share | 4.30 |
| Equity (Book Value) | 1.62B |
| Book Value Per Share | 4.96 |
| Working Capital | 1.33B |
Cash Flow
In the last 12 months, operating cash flow was -931.02 million and capital expenditures -11.57 million, giving a free cash flow of -942.59 million.
| Operating Cash Flow | -931.02M |
| Capital Expenditures | -11.57M |
| Free Cash Flow | -942.59M |
| FCF Per Share | -2.89 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -903.19% |
| Pretax Margin | -733.69% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,357.47% |
Dividends & Yields
Nykode Therapeutics AS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.11% |
| Shareholder Yield | -17.11% |
| Earnings Yield | -20.06% |
| FCF Yield | -44.82% |
Stock Splits
The last stock split was on July 7, 2020. It was a forward split with a ratio of 5.
| Last Split Date | Jul 7, 2020 |
| Split Type | Forward |
| Split Ratio | 5 |